Translating science into service: Lessons learned from the sequenced treatment alternatives to relieve depression (STAR*D) study

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 9, Issue 5, 2007, Pages 331-337

  Sussman, Norman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; NORTRIPTYLINE; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE;

ALTERNATIVE MEDICINE; CLINICAL PRACTICE; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; DRUG WITHDRAWAL; HEALTH CARE PERSONNEL; HUMAN; MAJOR DEPRESSION; MEDICAL CARE; MEDICAL EDUCATION; MEDICAL SERVICE; MENTAL HEALTH; MONOTHERAPY; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 36248952573     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v09n0501     Document Type: Review

References (44)

1. Rosenbaum JF. Introduction. Depression and its subtypes: a treatment update. J Clin Psychiatry 1998;59 (suppl 18):3-4
2. World Health Organization. World Health Organization. Executive summary. Available at: www.who.int/whr/1997/media_centre/executive_summary1/en/index14. html. Accessed Oct 12, 2006
3. Greden JF. The burden of recurrent depression: causes, consequences, and future prospects. J Clin Psychiatry 2001;62(suppl 22):5-9
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105
5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
6. Murray CJ, Lopez AD, eds. The Global Burden of Disease and Injury Series, vol 1: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press; 1996
7. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504
8. Sussman N. Understanding STAR*D findings. Prim Psychiatry 2006;13:12-13
9. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25:119-142
10. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345-351
11. Crismon ML, Trivedi M, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999;60:142-156
12. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61:669-680
13. Rubinow DR. Treatment strategies after SSRI failure: good news and bad news. N Engl J Med 2006;354:1305-1307
14. National Institute of Mental Health. Initial Results Help Clinicians Identify Patients With Treatment-Resistant Depression [press release]. Available at: http://www.nimh.nih.gov/press/stard.cfm. Accessed Oct 12, 2006
15. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
16. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am 2003;26:457-494
17. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
18. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60(suppl 22):7-11
19. Thase ME. The clinical, psychosocial, and pharmacoeconomic ramifications of remission. Am J Manag Care 2001;7:S377-S385
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
21. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
22. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
23. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):10-17
24. Trivedi MH, Kleiber BA. Using treatment algorithms for the effective management of treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 18):25-29
25. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):26-31
26. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):18-24
27. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry 2003;53:743-753
28. Belmaker RH. Bipolar disorder. N Engl J Med 2004;351:476-486
29. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242
30. Sussman N. Depression: augmentation or switch after initial SSRI treatment. N Engl J Med 2006;354:2611-2613
31. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
32. Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 2005;22:68-76
33. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-1172
34. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;163:1519-1530
35. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163:1531-1541
36. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917
37. Gaynes BN, Rush AJ, Trivedi M, et al. A direct comparison of presenting characteristics of depressed outpatients from primary vs specialty care settings: preliminary findings from the STAR*D clinical trial. Gen Hosp Psychiatry 2005;27:87-96
38. Rush AJ, Zimmerman M, Wisniewski SR, et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord 2005;87:43-55
39. Marcus SM, Young EA, Kerber KB, et al. Gender differences in depression: findings from the STAR*D study. J Affect Disord 2005;87:141-150
40. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol 1996;16:4S-14S
41. Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004;161:163-165
42. Thase ME. Overview of antidepressant therapy. Manag Care 2001;10 (suppl 8):6-9; 18-22
43. Ishak WW, Rapaport MH, Gotto JG. The effectiveness of atypical antipsychotic medications in depressive disorders. Curr Psychiatry Rep 2004;6:422-424
44. Macritchie KA, Young AH. Emerging targets for the treatment of depressive disorder. Expert Opin Ther Targets 2001;5:601-612